Pleco Therapeutics B.V. announced that it has entered into an agreement to receive 1 million in a round of funding from new investor Hyloris Pharmaceuticals SA on November 10, 2021.Under the terms, investor will provide 1 million automatically convertible into company's equity under certain conditions in several tranches over time. Subject to feedback from the FDA on the feasibility of the clinical development requirements, investor may commit to fund not convertible into equity up to an additional 7.7 million in pre-defined research and development activities through to submission for approval in AML, plus initial exploratory development work in SCLC.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.7 EUR | -1.27% | -2.50% | -8.24% |
Mar. 14 | Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024 | CI |
Mar. 14 | Transcript : Hyloris Pharmaceuticals SA, 2023 Earnings Call, Mar 14, 2024 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.24% | 355M | |
+25.83% | 653B | |
+27.00% | 556B | |
-6.76% | 354B | |
+20.34% | 331B | |
+3.00% | 296B | |
+13.09% | 233B | |
+5.46% | 201B | |
-9.61% | 193B | |
-6.26% | 144B |
- Stock Market
- Equities
- HYL Stock
- News Hyloris Pharmaceuticals SA
- Pleco Therapeutics B.V. announced that it expects to receive €1 million in funding from Hyloris Pharmaceuticals SA, Oost NL BV